سعر سولبادول 2.5مجم 6 اقراص ذائبة بالفم 2024

Zolmitriptan 2.5 mg orally disintegrating tablets, pack of 6 (Solpadol, Global Napi Pharmaceuticals, Egypt); selective 5-HT1B/1D agonist for acute migraine.

• Acute treatment of migraine with or without aura in adults. Not indicated for the preventive treatment of migraine or for cluster headache.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (≥5% and greater than placebo): neck/throat/jaw pain, tightness or pressure; dizziness; paresthesia; asthenia; somnolence; warm/cold sensation; nausea; heaviness sensation; and dry mouth.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, documented silent ischemia) or coronary artery vasospasm including Prinzmetal's angina.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• History of stroke, transient ischemic attack, or hemiplegic or basilar migraine; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Myocardial ischemia, infarction and Prinzmetal's angina: perform cardiovascular evaluation in triptan-naive patients with multiple cardiovascular risk factors before use; consider first dose under medical supervision with ECG.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Arrhythmias; chest, throat, neck and/or jaw pain, tightness or pressure (usually non-cardiac, but evaluate high-risk patients); cerebral hemorrhage, subarachnoid hemorrhage and stroke; gastrointestinal and peripheral vasospastic ischemia; significant blood pressure elevation.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Medication overuse headache may result from overuse of acute migraine drugs (10 or more days per month); detoxification may be necessary.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Ergot-containing drugs and other 5-HT1B/1D agonists (triptans)Additive prolonged vasospastic reactions; use within 24 hours of each other is contraindicated.DailyMed (U.S. National Library of Medicine)
• MAO-A inhibitorsIncrease zolmitriptan systemic exposure; use of zolmitriptan within 2 weeks of an MAO-A inhibitor is contraindicated.DailyMed (U.S. National Library of Medicine)
• CimetidineDoubles the half-life and AUC of zolmitriptan; limit the maximum single dose to 2.5 mg, not exceeding 5 mg in any 24-hour period.DailyMed (U.S. National Library of Medicine)

• No adequate data on developmental risk in pregnant women; in animal studies zolmitriptan caused embryolethality and fetal abnormalities at exposures above those in humans.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No data on zolmitriptan in human milk; in rats milk levels were up to 4 times plasma levels; weigh breastfeeding benefits against the mother's need.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Zolmitriptan: Selective agonist at serotonin 5-HT1B and 5-HT1D receptors; relief of migraine is thought to result from vasoconstriction of intracranial blood vessels and inhibition of pro-inflammatory neuropeptide release from trigeminal nerve endings.